Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

NCT02727660
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder
Interventions
BFF MDI (PT009) 320/9.6 μg, BFF MDI (PT009) 160/9.6 μg, FF MDI (PT005) 9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
121
States / cities
Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

NCT01728220
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

Dynamic Hyperinflation and Tiotropium

NCT00569270
View directory record Official record
Conditions
COPD
Interventions
Placebo
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Respiration Rate Monitoring in COPD Patients

NCT03030313
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Reassure Non-Contact Respiration Monitor
Device
Lead sponsor
ResMed
Industry
Eligibility
35 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Determining the Benefits of Improving Communication in BPAP/CPAP Users

NCT03795753
View directory record Official record
Conditions
Positive-Pressure Respiration, Communication
Interventions
F2S Communicator, Non-functioning Communicator
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 4, 2026, 6:54 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

NCT01043601
View directory record Official record
Conditions
COPD
Interventions
Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Dose Finding Study in COPD

NCT00122434
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 83 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 4, 2026, 6:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Airvo 3 Respiratory Rate Validation Study

NCT06329609
View directory record Official record
Conditions
COPD, Healthy Volunteers
Interventions
Airvo 3 with respiratory rate algorithm
Device
Lead sponsor
Fisher and Paykel Healthcare
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 4, 2026, 6:54 AM EDT
Terminated Not applicable Interventional Results available

Venovenous CO2 Removal (VVCO2R) in Patients With COPD and Acute Respiratory Failure

NCT00594009
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Venovenous CO2 Removal (VVCO2R) in COPD
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 4, 2026, 6:54 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effect of Steroids on Gene Expression in the Healthy Smokers Lungs

NCT00532584
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Beclomethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 4, 2026, 6:54 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

NCT03674320
View directory record Official record
Conditions
COPD
Interventions
Testosterone Enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00877383
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Effect of Curcumin on Lung Inflammation

NCT01514266
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Curcumin+Bioprine, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00691405
View directory record Official record
Conditions
COPD
Interventions
Arformoterol tartrate inhalation solution, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
31
States / cities
Encinitas, California • Long Beach, California • Brandon, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 4, 2026, 6:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fat Metabolism in OSA and COPD

NCT02157844
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Obesity
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Not applicable Interventional

A Cognitive-Behavioral Intervention for Depression and Anxiety in COPD

NCT00105911
View directory record Official record
Conditions
Depressive Disorders, Anxiety Disorders, Pulmonary Disease, Chronic Obstructive
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

NCT00900731
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 4 Interventional

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

NCT00115492
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol Combination Product, Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
95
States / cities
Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Adjusting to Chronic Conditions Using Education, Support, and Skills

NCT01149772
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Heart Failure, Anxiety, Depression
Interventions
ACCESS
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316900
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444, tiotropium bromide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 4, 2026, 6:54 AM EDT
Active, not recruiting No phase listed Observational

Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease

NCT05955482
View directory record Official record
Conditions
COPD, Comorbidities and Coexisting Conditions
Interventions
NuvoAir Clinical Service
Other
Lead sponsor
NuvoAir Medical PC
Industry
Eligibility
30 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00676052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg, GSK233705 100mcg, GSK233705 200mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Jasper, Alabama • Glendale, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)

NCT02347774
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo eFlow (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
45
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 4, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

NCT01691482
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol/salbutamol, Ipratropium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 4, 2026, 6:54 AM EDT